Compare PSTL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTL | GYRE |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.6M | 624.9M |
| IPO Year | 2018 | 2004 |
| Metric | PSTL | GYRE |
|---|---|---|
| Price | $23.89 | $6.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $20.19 | $17.00 |
| AVG Volume (30 Days) | ★ 282.8K | 66.5K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | ★ 123.81 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $95,823,000.00 | $275,000.00 |
| Revenue This Year | $18.01 | $19.88 |
| Revenue Next Year | $11.38 | N/A |
| P/E Ratio | $214.86 | ★ N/A |
| Revenue Growth | ★ 25.47 | N/A |
| 52 Week Low | $13.17 | $5.97 |
| 52 Week High | $23.87 | $11.61 |
| Indicator | PSTL | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 69.61 | 32.79 |
| Support Level | $22.15 | N/A |
| Resistance Level | $23.87 | $8.26 |
| Average True Range (ATR) | 0.67 | 0.38 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 93.85 | 4.34 |
Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.